To further confirm the regulatory axis between MAPK activation and IL-17 regulators, we demonstrated, by pharmacologic manipulation in vitro, that IL-17-inducing genes can be expressed by BRAF-mutant melanoma cells themselves, and dual MAPKi (dabrafenib plus trametinib) leads to decreased transcription of IL-17-regulatory genes (Extended Data Fig. 1e). Here, IL17A is linked to melanoma.